Executing well: another outlook upgrade and aggressively eyeing growth
14/11/25 -"The Q3 results surpassed expectations, driven by strong demand for depression and migraine medicines. Consequently, the management upgraded its full-year guidance for the third time this year. ..."
Pages
56
Language
English
Published on
14/11/25
You may also be interested by these reports :
14/11/25
The Q3 results surpassed expectations, driven by strong demand for depression and migraine medicines. Consequently, the management upgraded its ...
13/11/25
The Q3 results exceeded the street’s expectations, driven by healthy top-line growth across all segments and a profitability beat (also aided by a ...
12/11/25
The Q3 profitability beat was driven by Crop Science, though Pharmaceuticals witnessed lower operating profits. Also, the management maintained its ...
10/11/25
The US government has agreed with Novo and Lilly to lower their weight-loss drugs’ prices, mainly in return for a three-year tariff exemption and ...